Clinical Trials · NCT02079870
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 30
- Start date
- Mar 2014
- Locations
- 1 site, United Kingdom
- Primary endpoint
- Ad libitum energy intake during a lunch meal (following a standardised breakfast meal)